Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Significant Accounting Policies (Tables)

v3.26.1
Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2025
Significant Accounting Policies [Abstract]  
Schedule of Depreciable Rates of Property and Equipment Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:

 

    %     Mainly
%		  
             
Laboratory equipment   10     10  
             
Computers, office furniture and equipment   6 - 33     33  
Schedule of Major Customer Data as a Percentage

Major customer data as a percentage of total revenues:

 

    Year ended December 31,  
    2025     2024     2023  
                   
Cipher Pharmaceuticals (Canada)     11 %     7 %     11 %
Chong Kun Dang Pharmaceuticals Corp. (South Korea)     19 %     11 %     25 %
Gebro Holding GmbH (Austria)     19 %     11 %     18 %
Ewopharma AG (Switzerland)     51 %     30 %     46 %
Vetbiolix (France)     - %     41 %     -  
                         
Total     100 %     100 %     100 %
Schedule of Antidilutive Shares

All outstanding share options and warrants for the years ended December 31, 2025, 2024 and 2023 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. The potential ordinary shares and warrants that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows:

 

    Year ended December 31,  
    2025     2024     2023  
                   
Options     49,533       41,610       27,492  
Warrants     2,604,096       886,599       617,337  
                         
Total     2,653,629       928,209       644,829  

 

(*) Retroactively adjusted to give effect to the reverse share split, see also note 9.